drugset
Drugs / SB-705498
last change Oct 2012 re-read 2 minutes ago

SB-705498

also known as GSK705498

Small molecule targets TRPV1 via inhibition

Developed for
rhinitis · irritable bowel syndrome · migraine disorder
Investigated by
GlaxoSmithKline

Trials 8 · a red edge is where a trial was stopped

today NCT01673529 · Ph 1 NCT01424397 · Ph 2 NCT01424514 · Ph 2 NCT00907933 · Ph 1 NCT00731250 · Ph 1 NCT00461682 · Ph 2 NCT00269022 · Ph 2 NCT00281684 · Ph 2
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT01673529 Jul → Oct 2012 atopic eczema GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00907933 Nov 2008 → Feb 2009 rhinitis GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00731250 Jul 2008 → Mar 2009 rhinitis GlaxoSmithKline Completed No outcome recorded
Phase 25 trials
Phase 2 NCT01424397 Apr → Jul 2011 rhinitis GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT01424514 Dec 2010 → Apr 2011 rhinitis GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00461682 Jan → Sep 2007 irritable bowel syndrome GlaxoSmithKline Terminated No outcome recorded
Phase 2 NCT00269022 Jan 2006 → ? migraine disorder GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00281684 Dec 2005 → Oct 2007 — GlaxoSmithKline Completed No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01476098 Comparator Apr → Dec 2011 rhinitis GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT01439308 Comparator Dec 2009 → Apr 2010 rhinitis GlaxoSmithKline Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

FieldValueCited text
Known as SB-705498 “A Multi-centre, Randomised, Single Blind, Placebo Controlled, Parallel Group Study to Examine the Effect of Single Doses of SB-705498, a TRPV1 Receptor Antagonist, on Pain...” NCT00281684 ↗
10

NCT01424397 ↗

NCT00269022 ↗

NCT01673529 ↗

NCT00281684 ↗

NCT01424514 ↗

NCT01476098 ↗

NCT01439308 ↗

NCT00731250 ↗

NCT00907933 ↗

NCT00461682 ↗
Known as GSK705498 ChEMBL registry synonym — accepted as the source's own label CHEMBL207433 ↗
Action Inhibit “inhibition of TRPV1 with SB-705498 can both prevent and reverse established central sensitisation.” NCT00269022 ↗
Modality Small molecule — CHEMBL207433 ↗
Route Oral “Eligible participants received a single dose of SB705498 400 milligram (mg) capsules (2 x 200 mg capsules plus 2 placebo capsules) via oral route and were followed up to a...” NCT00281684 ↗
Target TRPV1 “TRPV1 receptor antagonist” NCT00269022 ↗